Table 4.
Gene | Lymphoma | ||
---|---|---|---|
BL | HD | Iatrogenic/AIDS-associated | |
ABF1 | + | − | |
BCL2-family (proapoptotic members) | + | ||
BCMA | + | ||
BOB.1/OBF.1 | + | ||
CHK2 kinase | + | ||
Cyclin D2 | + | ||
CD19 | + | ||
CD20 | + | ||
CD79B | + | ||
CD59/HRF20 | + | ||
DAPK | + | ± | + |
DLC1 | + | ± | |
FHIT | + | ||
GADD25G | + | ||
GSTP1 | + | ||
LCK | + | ||
MAPK10/JNK3 | + | ± | |
O6-methylguanine-DNA MTase | + | ||
p16/CDK4A | + | ± | − |
p15/CDK4B | + | ± | − |
p57/KIP2 | + | ||
p73 | + | ||
PCDH10 | + | + | |
PLK2 | + | ||
PU.1 | + | ||
PTPN13/FAP1 | + | ||
RASSF1A | − | + | − |
SYK | + | ||
WNT5A | + |
BL: Burkitt’s lymphoma; HD: Hodgkin’s disease; iatrogenic lymphomas include post-transplant lymphoproliferative disorders (PTLDs) and methotrexate-related lymphomas.
Symbols: frequent inactivation by promoter methylation, +; infrequent inactivation by promoter methylation, −/+; typically unmethylated promoter, −.